8.1.4 Post-study Treatment Study Follow-up Post-study follow-up is of critical importance and is essen tial to preserving participant safety and the integrity of the study. Participants who discontinue study treatment must continue to be followed up for the collection of outcome and/or survival fo llow-up data as required and in line with Section 5 until death or the conclusion of the study. BMS may request that survival data be collected on all treated/randomized participants outside of the -defined window ( Section 2 ). At the time of this request, each participant will be contacted to determine his or her survival status unless the participant has withdrawn consent for all con tacts or is lost to follow-up. Participants who discontinue study treatment may continue to be followed up.8.2 Discontinuation from the Study Participants who request to discontinue study treatment will remain in the study and must continue to be followed up for protocol-specified follow-up procedures, as indicated in Section 5.1.3 . The only exception to this is when participants specifically withdraw consent for any further contact with them or persons previously authorized by participants to provide this information. •Participants should notify the investigator of the decision to withdraw consent from future follow-up in writing, whenever possible. •The investigator should explain the withdrawal of consent in detail in the medical records and enter on the appropriate CSR page as to whether the withdrawal is from further treatment with study treatment only or also from study procedures and/or post-treatment study follow-up; this explanation should be entered on the appropriate CRF page. •In the event that vital status (whether the participant is alive or dead) is being measured, publicly available information s hould be used to determine vital status only as appropriately directed in accordance with local law. •If the participant withdraws consent for disclosure of future i nformation, the Sponsor may retain and continue to use any data collected before such a withdrawal of consent. 8.3 Lost to Follow-up Guidelines for participants lost to follow-up include the following: •All reasonable efforts must be made to locate participants to determine and re port their ongoing status. This includes follow-up with persons authorized by the participant for contact. Revised Protocol No.: 04 Date: 31-May-2019 97 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS •Lost to follow-up is defined by the inability to reach the participant after a minimum of 3documented phone calls, faxes, or emails as well as lack of response by participant to 1registered mail letter. All attempts shoul d be documented in the participant’s medical records.